Closeup of Roger Sabbadini

Roger Sabbadini, Ph.D.

Pronouns: Roger

Emeritus Professor of Biology

College of Sciences
Department of Biology

Bend, Oregon

Phone
619 787-0570
Office Hours

By Appointment

Location
[room number]
[address]
[City, State, Zip]
Mail Code
[1234]
Fax
[619-594-####]
Accounts

Areas of Expertise

Bioactive Lipids, Sphingolipids, S1P (Sphingosine-1-Phosphate), LPA (Lysophosphatidic Acid), Antibody-Based Therapeutics, Neuropathic Pain, Cancer Therapeutics, Ocular Disorders, Inflammation, Heart Disease, Neurotrauma, Age-Related Macular Degeneration (AMD), Bacterial Minicells, Vaccine Development, Targeted Drug Delivery, DNA And Protein Antigen Delivery, Therapeutic Antibodies, Phase 1 And 2 Clinical Trials, Biotechnology, Biopharmaceuticals

Student Opportunities

  1. [Opportunity 1]
  2. [Opportunity 2]

Bio

Dr. Sabbadini was a Professor of Biology for 32 years at San Diego State University (SDSU) and is currently Emeritus Professor of Biology. He founded three biotechnology companies, including Lpath, Vaxiion and Mpex, incubated out of SDSU. Dr. Sabbadini has been interested in the role of bioactive lipids in disease, including cancer, ocular disorders, neurotrauma, neuropathic pain, inflammation and heart disease. 

Dr. Sabbadini’s research focused on developing novel antibody-based therapeutics against bioactive lipids such as the sphingolipids, S1P and LPA. Bioactive lipids can become dysfunctional and directly contribute to the pathophysiology of many disorders.

The anti-S1P antibody completed Phase 2 clinical trials for AMD and cancer. Sphingolipids multifunctional lipid mediators largely involved in signaling activities required for normal cellular function.  The anti-LPA antibody has completed a Phase 1a clinical study in healthy volunteers and may be used in the treatment of neuropathic pain.

Dr. Sabbadini is also interested in bacterial minicells as vectors for DNA and protein antigen delivery for therapeutic vaccine development and for targeted drug delivery in cancer.

Dr. Sabbadini earned his Ph.D. in physiology at the University of California, Davis. Sabbadini has 36 issued US patents.

Details

Courses
  1. [COURSE 1 – Title]
  2. [COURSE 2 – Title]
  3. [COURSE 3 – Title]
Education
  1. Ph.D. in Physiology, 1974
    University of California, Davis
  2. B.A. in Psychology, 1970
    University of California, Davis
Publications
  1. Sabbadini, Roger. Making a Difference. European Journal of Translational Myology Eur J Transl Myol 34(3): 63-80. 2024
  2. Sabbadini, Roger. Cathedrals of the mind and the vision of Nicholas Condorcet, Free Inquiry. Feb/Mar 44(2): 42-49. 2024
  3. Peethambaran, Arun Donna M. Wilder, Ying Wang, Andrew J. Morris, Roger Sabbadini Joseph B. Long . Cerebrospinal fluid levels of lysophosphatidic acids can be a suitable biomarker of blast-induced traumatic brain injury. J. of Neurotrauma 40(21-22). 2023
  4. Sabbadini, Roger. Truth, Relativism, and Identity Politics, The Skeptical Inquirer 46(6): 43-45. 2022 https://skepticalinquirer.org/2022/10/truth-relativism-and-identity- politics/ 2022
  5. Su, Lie, Emerson Krock, Swapnali Barde, Ada Delaney, Johnny Ribeiro, Jungo Kato, Nilesh Agalave, Gustaf Wigerblad , Rosalia Matteo, Roger Sabbadini, Anna Josephson, Jerold Chun, Kim Kultima, Olivier Peyruchaud, Tomas Hökfelt, Camilla I. Svensson. Pain-like behavior in the collagen antibody-induced arthritis model is regulated by lysophosphatidic acid and activation of satellite glia cells. Brain, Behavior and Immunity 101: 214-230. 2022
  6. Peethambaran, Arun, Franco Rossetti, James DeMar, Ying Wang, Andrew Batuure, Donna Wilder, Irene Gist, Andrew Morris, Roger Sabbadini and Joseph Long. Antibodies against lysophosphatidic acid protect against blast-induced ocular injuries. Frontiers in Neurology: Neurotrauma Section volume 11 article 611816. doi: 10.3389/fneur.2020.611816. 2020
  7. Lupino, L., T. Perry, S. Margielewska, R. Hollows, M, Ibrahim, M. Care, J. Allegood, R. Tooze, R. Sabbadini, G. Reynolds; R. Bicknell, Z. Rudzki, Y. L. Hock, U. Zanetto, W, Wei; W. Simmon, S. Spiegel, C. Woodman, M, Rowe, K. Vrzalikova, P. Murray. Sphingosine-1-Phosphate Signalling Drives an Angiogenic Transcriptional Programme In Diffuse Large B Cell Lymphoma. Leukemia 33(12):2884-2897. doi: 10.1038/s41375-019-0478-9. 2019
  8. McDonald, Whitney, E. Ellen Jones, Jonathan M. Wojciak, Richard R. Drake, Roger A. Sabbadini, and Neil G. Harris, MALDI Mapping of Lysophosphatidic Acid Changes After Traumatic Brain Injury: Relationship to Cellular Pathology, Am J. Pathol 188:1779-17793. 2018
  9. Reynolds, G., B. Visentin and R. Sabbadini. Immunohistochemical detection of sphingosine-1-phosphate and sphingosine kinase-1 in human tissue samples and cell lines. Methods Mol Biol.1697:43-56. 2018
  10. Eisenried A, Meidahl ACN, Klukinov M, Tzabazis AZ, Sabbadini RA, Clark JD, Yeomans DC. Nervous system delivery of antilysophosphatidic acid antibody by nasal application attenuates mechanical allodynia after traumatic brain injury in rats. Pain. 2017 Nov;158(11):2181-2188. 2017
  11. Andrieu G, Ledoux A, Branka S, Bocquet M, Gilhodes J, Walzer T, Kasahara K, Inagaki M, Sabbadini RA, Cuvillier O, Hatzoglou A. Sphingosine 1-phosphate signaling through its receptor S1P 5 promotes chromosome segregation and mitotic progression. Sci Signal. 2017 Mar 28;10(472). 2017
  12. Cheng J, S. S, Hausrat TJ, Yang JW, Ji H, Schmarowski N, Endle H, Liu X, Li Y, Böttche R, Radyushkin K, Maric HM, Hoerder-Suabedissen A, Molnár Z, Prouvot PH, Trimbuch T, Ninnemann O, Huai J, Fan W, Visentin B, Sabbadini R, Strømgaard K, Stroh A, Luhmann HJ, Kneussel M, Nitsch R, Vogt J. Precise Somatotopic Thalamocortical Axon Guidance Depends on LPA-Mediated PRG-2/Radixin Signaling. Neuron. 2016 Oct 5;92(1):126-142. 2017
  13. Tsuji S, Chen X, Hancock B, Hernandez V, Visentin B, Reil K, Sabbadini R, Giacalone M, Godbey WT. Preclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancer. Mol Ther Oncolytics. 2016 Mar 16;3:16004. 2016
  14. Bouquerel P, Gstalder C, Müller D, Laurent J, Brizuela L, Sabbadini RA, Malavaud B, Pyronnet S, Martineau Y, Ader I, Cuvillier O. Essential role for SphK1/S1P signaling to regulate hypoxia-inducible factor 2 a expression and activity in cancer. Oncogenesis. 2016 Mar 14;5:e209. doi: 10.1038/oncsis.2016.13. 2016
  15. Sattler K, Gräler M, Keul P, Weske S, Reimann CM, Jindrová H, Kleinbongard P, Sabbadini R, Bröcker-Preuss M, Erbel R, Heusch G, Levkau B. Defects of High-Density Lipoproteins in Coronary Artery Disease Caused by Low Sphingosine-1-Phosphate Content: Correction by Sphingosine-1-Phosphate-Loading. J Am Coll Cardiol. Sep 29;66(13):1470-85. 2015
  16. Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, Moreno K, Visentin B, Deutschman D, Alsop DC, Atkins MB, Mier JW, Signoretti S, Bhasin MK, Sabbadini RA, Bhatt RS. Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI resistant renal cancer. Clin Cancer Res. 2015 Apr 15;21(8):1925-34 2015
  17. Ader, I, Gstalder C, Bouquerel P, Golzio M, Andrieu G, Zalvidea S, Richard S, Sabbadini RA, Malavaud B, Cuvillier O. Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodeling and sensitizes to chemotherapy in prostate cancer. Oncotarget 6(15): 13803-21. 2015
  18. Weth, D., C. Benetti, C. Rauch, G. Gstraunthaler, H. Schmidt, G. Geisslinger, R. Sabbadini, R.L. Proia, M. Kress. Activated platelets release sphingosine 1-phosphate and induce hypersensitivity to noxious heat stimuli in vivo. Front. Neurosci. Apr 22;9:140 1-8. 2015
  19. Trayssac, M., S. Galvani, N, Augé, Roger Sabbadini, D. Calise, E. Mucher, F. Sallusto, M. Thomsen, R. Salvayre, A. Nègre-Salvayre. Role of Sphingosine-1-Phosphate in transplant vasculopathy evoked by anti-HLA antibody. Am J Transplant Aug;15(8):2050-61 2015
  20. Brizuela L, Martin C, Jeannot P, Ader I, Gstalder C, Andrieu G, Bocquet M, Laffosse JM, Gomez-Brouchet A, Malavaud B, Sabbadini RA, Cuvillier O. Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells. Mol. Oncol;8(7):1181-95. 2014
  21. Crack, P. J., M. Zhang, M. C. Morganti-Kossmann, A. Morris, J. M Wojciak, I. Karve, D. Wright, M. Sashindranath, Y. Goldshmit, A. Conquest, M, Daglas, L.A Johnston, R. L. Medcalf, R. A Sabbadini and A. Pébay. Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes. J Neuroinflammation 11(1):37. 2014
  22. Slattum, G., Y. Gu, R. Sabbadini and J. Rosenblatt. Autophagy in oncogenic K-Ras promotes basal extrusion of epithelial cells by degrading S1P Current Biol. 24: 1-10. 2014
  23. Sabbadini, R., J. M. Wojciak, K, Moreno, and B. Visentin. Antibodies to bioactive lysophospholipids in Lysophospholipid Receptors: Signaling and Biochemistry ed. J. Chun, et al. John Wiley, 2013
  24. Finley A, Chen Z, Esposito E, Cuzzocrea S, Sabbadini R, Salvemini D. Sphingosine 1-Phosphate Mediates Hyperalgesia via a Neutrophil-Dependent Mechanism. PLoS One 8(1):e55255. doi: 10.1371/journal.pone.0055255. Epub 2013 Jan 25 2013
  25. Goldshmit Y, Matteo R, Sztal T, Ellett F, Frisca F, Moreno K, Crombie D, Lieschke GJ, Currie PD, Sabbadini RA and Pébay A. Blockage of lysophosphatidic acid signalling improves spinal cord injury outcomes. Am J Pathol. Sep; 181(3):978-92. 2012
  26. Frisca, F., Sabbadini, R.A., Goldshmit, Y. & Pebay, A. Biological Effects of Lysophosphatidic Acid in the Nervous System. International Review of Cellular and Molecular Biology 296:273-322. 2012
  27. Ponnusamy, S, S.P. Selvam, S. Mehrotra,T. Kawamori, A. J. Snider, L. M. Obeid, Y. Shao, R. Sabbadini, B. Ogretmen. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1- phosphate signalling to regulate tumour metastasis. EMBO Mol Med. Aug;4(8):761- 75. 2012
  28. Gu Y, Forostyan T, Sabbadini R, Rosenblatt J. Epithelial cell extrusion requires the sphingosine-1-phosphate receptor 2 pathway. *Journal of Cell Biology* May 16;193(4):667-76, 2011.
  29. Berdyshev EV, Gorshkova I, Usatyuk P, Kalari S, Zhao Y, Pyne NJ, Pyne S, Sabbadini RA, Garcia JG, Natarajan V. Intracellular S1P Generation Is Essential for S1P-Induced Motility of Human Lung Endothelial Cells: Role of Sphingosine Kinase 1 and S1P Lyase. *PLoS One* Jan 31; 6(1):e16571, 2011.
  30. Sabbadini, R. A. Sphingosine-1-Phosphate Antibodies as Potential Agents in the Treatment of Cancer and Age-related Macular Degeneration. *British Journal of Pharmacology* Mar; 162(6):1225-38, 2011.
  31. Wojciak, J., N. Zhu, K. Schuerenberg, K. Moreno, W. Shestowsky, M. Hiraiwa, R. Sabbadini and T. Huxford. The crystal structure of sphingosine-1-phosphate in complex with a Fab fragment reveals metal bridging of an antibody and its antigen. *Proceedings of the National Academy of Sciences* Oct 20; 106(42):17717-22, 2009.
  32. O’Brien N, Jones ST, Williams DG, Cunningham HB, Moreno K, Visentin B, Gentile A, Vekich J, Shestowsky W, Hiraiwa M, Matteo R, Cavalli A, Grotjahn D, Grant M, Hansen G, Campbell MA, Sabbadini R. Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. *Journal of Lipid Research* 50:2245-2257, 2009.
  33. Gellings Lowe, N., James S. Swaney, Kelli M. Moreno, and Roger A. Sabbadini. Sphingosine-1-phosphate and sphingosine kinase are critical for TGF-alpha-stimulated collagen production by cardiac fibroblasts. *Cardiovascular Research* 2009 May 1;82(2):303-12. Epub Feb 19, 2009.
  34. Caballero, S., K. Moreno, G. Stoller, A. Cavalli, Wm, Garland, G. Hansen, R. Sabbadini and M. Grant. Anti-sphingosine-1-phosphate monoclonal antibody inhibits angiogenesis and sub-retinal fibrosis in a murine model of laser induced choroidal neovascularization. *Experimental Eye Research* Mar; 88(3):367-77, 2009.
  35. Swaney, J., K. M. Moreno, A. M. Gentile, R. A. Sabbadini and G. L. Stoller. Sphingosine-1-phosphate (S1P) is a novel fibrotic mediator in the eye. *Experimental Eye Research* Oct; 87(4):367-75, 2008.
  36. Zanin, M., E. Germinario, L. Dalla Libera, D. Sandonà, R. Sabbadini, R. Betto and D. Danieli-Betto. Trophic action of sphingosine-1-phosphate in denervated rat soleus muscles. *American Journal of Physiology – Cell Physiology* 294:C36-46, 2008.
  37. Giacalone, M. A, J. A. Zapata, N. L. Berkley, R. A. Sabbadini, Y. L. Chu, M. Salvato and K. L. McGuire. Immunization with non-replicating bacterial minicells delivering both protein antigen and DNA antigens protects mice from lethal challenge with Lymphocytic Choriomeningitis Virus. *Vaccine* 25:2279-2287, 2007.
  38. Giacalone, M. A., M. Gentile, B. T. Lovitt, M. W. Surber and R. Sabbadini. Bacterial minicells can target and transfer plasmid DNA to eukaryotic cells. *Cellular Microbiology* 8:1624-1633, 2006.
  39. Giacalone, M. A, R. A. Sabbadini, A. L. Chambers, S. Pillai and K. McGuire. Immune responses elicited by bacterial minicells capable of simultaneous DNA and protein antigen delivery. *Vaccine* 24:6009-17, 2006.
  40. Sabbadini, R.A. Targeting sphingosine-1-phosphate for cancer therapy. *British Journal of Cancer* 95:1131-5, 2006.
  41. Visentin, B., J. Vekich, J., B. Sibbald, A. Cavalli, R. Matteo, K. Moreno, Wm. Garland, Y. Lu, F. Xing, V. Kumar, G. Mills and R. Sabbadini. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. *Cancer Cell* 9:225-238, 2006.
  42. Danieli-Betto, D., E. Germinario, A. Esposito, A. Megeghian, M. Midrio, B. Ravara, E. Damiani, L. Dalla Libera, R.A. Sabbadini, and R. Betto. Sphingosine-1-phosphate protects mouse EDL skeletal muscle during fatigue. *American Journal of Physiology* 288:C1367-73, 2005.
  43. Deutschman, D., Carstens, J.S., R.L. Klepper, W.S. Smith, M.T. Page, T.R. Young, L. Gleason, N. Nakajima, and R.A. Sabbadini. Predicting coronary artery disease using serum sphingosine-1-phosphate. *American Heart Journal* 146:62-68, 2003.
  44. O’Brien, N., N. Gellings, M. Guo, C.C. Glembotski, and R.A. Sabbadini. Molecular Identification of Rat FAN and its Role in hypoxia reoxygenation induced cell death in cardiomyocytes. *Circulation Research* 92:589-91, 2003.
  45. Cavalli, A., N. O’Brien, S. Barlow, R. Betto, C. Glembotski, P. Palade, and R. Sabbadini. Expression and functional characterization of SCaMPER: A calcium channel of cardiomyocytes. *American Journal of Physiology* 284:C780-C790, 2003.
  46. Cavalli, A.L., J.A. Ligutti, N.M. Gellings, E. Castro, M.T. Page, R.E. Klepper, and R.A. Sabbadini. The role of TNF and sphingolipid signaling in cardiac hypoxia: Evidence that cardiomyocytes release TNF and sphingosine. *Basic and Applied Myology* 12:159-167, 2002. http://www.bio.unipd.it/~bam/02493Cavalli.pdf
  47. Betto, R., A. Teresi, F. Turcato, M. Duca, D. Danieli-Betto, and R. Sabbadini. Inability of sphingosine and calmodulin to control ryanodine receptor in malignant hyperthermia. *Basic and Applied Myology* 12:167-176, 2002. http://www.bio.unipd.it/~bam/02489Betto.pdf
  48. Dalla Libera, L., R. Sabbadini, B. Ravara, M. Sandri, R. Betto, and G. Vescovo. Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF and sphingosine. *Journal of Molecular and Cellular Cardiology* 31:1871-1878, 2001.
  49. Krown, K. and R. A. Sabbadini. Preparation and Use of Myocardial Cells in Culture to Study Effects of Cytokines in *Methods in Molecular Medicine: Septic Shock Methods and Protocols*. Humana Press. Ed. T. Evans. 36:181-188, 2000.
  50. Page, M.T., P.J.E. Quintana, J. A. Ligutti and R. A. Sabbadini. Cell death in cultured adult rat cardiomyocytes: use of the COMET assay to distinguish apoptosis from necrosis. *Basic and Applied Myology* 10: 159-170, 2000.
  51. Nakajima, N.J. A. Ligutti, A. L. Cavalli, D. Biral, C.C. Glembotski, P. M. McDonough, P. D. Ho, R. Betto, D. Sandona, P. T. Palade, C. A. Dettbarn, R. E. Klepper and R. A. Sabbadini. Expression and characterization of Edg-1 receptors in rat cardiomyocytes: Calcium deregulation in response to sphingosine-1-phosphate. *European Journal of Biochemistry* 267: 5679-5686, 2000.
  52. Ligutti, J., Nakajima, N., Cavalli, A.L, Betto, R., Biral, D., Sabbadini, R. G protein-coupled receptors, calcium deregulation and apoptosis in the heart. *Basic and Applied Myology* 10: 75-76, 2000.
Presentations
  1. Invited Speaker and session chair, University of Padova Symposium “Giovanni Salviati Legacy”. Montegrotto, Italy March 14-16, 2018.
  2. Invited Speaker Echelon Biosciences. Salt Lake City, UT. July, 2017.
  3. Invited Speaker Department of Basic Medical Sciences University of Arizona, College of Medicine- Phoenix. October 8, 2015.
  4. Invited Speaker, the FASEB summer conference on Lysophospholipids and related mediators-from Bench to clinic, Banff, Alberta, Canada. Aug 23-28, 2015.
  5. Keynote Speaker 30 th Annual Graduate Student Symposium, San Diego State, April 10, 2015.
  6. Invited speaker Medical University of South Carolina. November 12, 2014.
  7. Keynote speaker of 49th Annual South Eastern Regional Lipid Conference (SERLC); High Hampton Inn, Cashiers, North Carolina, November 5th to 7th, 2014.
  8. Invited Speaker. Puerto Rico Urological Association San Juan, Puerto Rico, Sept 25-29, 2014.
  9. Invited Speaker. UC Neurotrauma Symposium at Quail Lodge, Carmel CA Sept 14-16, 2014.
  10. Invited Speaker Gordon Conference on Glycobiology and Sphingolipid Biology, Jan 12-17, 2014, Ventura, CA.
  11. Invited Speaker 7 th Annual Pain Therapeutics Summit West, November 7-8, 2013 San Diego.
  12. Invited Speaker 7 th Annual Pain Therapeutics Summit East, September 25-26, 2013 Boston.
  13. Invited Speaker 2013 FASEB Science Research Conference entitled “Lysophospholipid and other related mediators- from bench to clinic. Sapporo, Hokkaido Japan Aug 4-9, 2013.
  14. Invited Seminar Speaker UCLA Department of Neurosurgery, June 11, 2013.
  15. Invited Seminar Speaker UC Davis Biotechnology Seminar, May 24, 2013.
  16. Speaker 3 rd Annual Arrowhead Traumatic Brain Injury Conference, March 6-7, 2013 Washington, DC US.
  17. Speaker at EMBO Workshop on Molecular Medicine of Sphingolipids, Ramos, Israel, October 16-21, 2012.
  18. Keynote address. San Diego State University graduation ISCOR Program May 18 th , 2012.
  19. Invited seminar speaker Blast-Induced Neurotrauma Branch Center for Military Psychiatry & Neuroscience Walter Reed Army Institute of Research, Silver Springs, MD. March 8 th , 2012.
  20. Invited seminar speaker UCLA Brain Injury Research Institute, August 31, 2011.
  21. National Cancer Institute SBIR Workshop, July 27, 2011 Bethesda, MD.
  22. Invited Keynote Speaker and Facilitator, Hollings Cancer Center Lipid Signaling in Cancer Program, Dec., 16, 2010. Charleston, SC.
  23. Symposium Speaker Experimental Biology meeting (Molecular Pharmacology division of the American Society of Pharmacology & Experimental Therapeutics), Anaheim, CA, April 24-28, 2010.
  24. Invited Speaker at the NCI SBIR Partnership Forum, Boston University, Boston, MA, November 5, 2009.
  25. Seminar speaker at the Medical University of South Carolina, Department of Biochemistry and Molecular Biology Hollings Cancer Center. October 15, 2009.
  26. Plenary Speaker Bioactive Lipids in Cancer, Inflammation and Related Diseases in Cancun, Mexico, October 25-28, 2009.
  27. Invited Speaker at annual meeting of the Licensing Executives Society in San Francisco, October 19, 2009.
  28. Invited Speaker at FASEB Summer Conference on Lysophospholipid Mediators in Health and Disease, Carefree, AZ. June 28, 2009.
  29. Invited Speaker on SBIR webinar sponsored by the National Council of Entrepreneurial Tech Transfer June 11, 2009.
  30. Invited Speaker INSERM and IPBS, Institut de Pharmacologie et de Biologie Structurale of the CNRS. Toulouse, France May 24, 2009.
  31. Invited Speaker American Assoc. of Cancer Researchers (AACR) 100 th annual meeting. Denver April 20, 2009.
  32. Invited Speaker International Society of Heart Research (ISHR) Bologna, Italy June 21-26, 2007.
  33. Invited Speaker Fifth Annual Meeting of the Sphingolipid Club, Nov. 2-4., 2006 Calella de la Costa , Spain.
  34. Invited Speaker, INSERM Istitut Universitaire d’Hematologie, Hopital Saint-Louis, Paris, France September 18, 2006.
  35. Invited Speaker, U.S. Patent and Trademark Office, April 17, 2006.
  36. Seminar Speaker, University of Arkansas School of Medicine, March 13, 2006.
  37. Seminar Speaker, SDSU Molecular Biology Institute. December 1, 2005.
  38. Seminar Speaker, Tarzana Regional Medical Center, October 21, 2005.
  39. Seminar Speaker, Computational Science Research Center, SDSU, September 30, 2005.
  40. Invited Speaker, Eicosanoids and other bioactive lipids in cancer, inflammation and related disease 9 th International Conference. September 11 – 14, 2005.
  41. Seminar Speaker, University of Hong Kong Medical School, September 1, 2005.
  42. Seminar Speaker, Computational Science Research Center, SDSU, February 18, 2005.
  43. Seminar Speaker, Point Loma Nazarene University, February 8, 2005.
  44. Seminar Speaker, Department of Experimental Biomedical Science, University of Padova, Italy, November 22, 2004.
  45. Seminar Speaker, MD Anderson Cancer Center, October 28, 2004.
  46. Invited Speaker, FASEB Summer Conference on Lysophospholipids and Related Bioactive Lipids in Biology and Diseases, Snowmass Village, Colorado, June 28 – July 3, 2003.
  47. Invited Speaker, European AIM conference, Padova, Italy June 14-17, 2003.
  48. Seminar Speaker, Department of Chemistry, SDSU, October 9, 2002.
  49. Seminar Speaker, Department of Chemistry, Univ. of California, Santa Barbara, April 9, 2002.
  50. Phil Beta Kappa Distinguished Lecture, May 27, 2002, San Diego State University.
  51. Keynote Speaker, College of Sciences Evening Forum, SDSU, October 25, 2001.
  52. Invited Speaker, Forth International Summit on Markers in Cardiology. October 11-12, 2001. Heart + Lung Institute Louisville, KY
Service
  1. [A]
  2. [B]
  3. [C]
Grants
  1. [A]
  2. [B]
  3. [C]
Clinical Trials
  1. [A]
  2. [B]
  3. [C]
Awards & Honors
  1. Awarded Professor of Biology Emeritus status, San Diego State University 2008.
  2. Outstanding Faculty Alumni Association Award for 2006, SDSU College of Sciences.
  3. California State University System-wide CSUPERB outstanding faculty research award 2005.
  4. Five Year Service Award from the American Heart Association, 2005.
  5. Wang Family Excellence Award for distinguished scholarship at SDSU, 2002.
  6. Designated Phi Beta Kappa Distinguished Lecturer, 2002.
  7. Presidential Award as one of 25 Most Influential Members of the SDSU Community, 2001.
  8. Raine Visiting Professorship, University of Western Australia, 1997 – a competitive award.
  9. SDSU Research, Scholarship and Creative Activity Awards (twice awarded), 1996&1997.
  10. Performance Salary Step Increase, 1997 (a competitive faculty award at SDSU).
  11. Recipient of first annual Teacher Scholar Award 1996 SDSU Department of Biology.
  12. Visiting Professor, Institute of General Pathology University of Padova 1-84 to 8-84; 10-90 to 1-91.
  13. Meritorious Performance and Professional Promise Award SDSU, 1988.
  14. Outstanding Faculty Award San Diego State University, 1984.
  15. Honorary Member Alpha Epsilon Delta.
  16. Postdoctoral Fellowship from the Muscular Dystrophy Assoc. 1-1975 to 8-1977.
  17. Herzendorf Memorial Award as outstanding Ph.D. student Univ. of Calif., Davis, 1974.
Patents & Copyrights
  1. 9,670,270 Minicell based delivery of biologically active compounds
  2. 9,274,130 Prevention and treatment of pain using antibodies to lysophosphatidic acid
  3. 9,274,129 Methods and reagents for detecting bioactive lipids
  4. 9,217,749 Immune-derived moieties reactive against lysophosphatidic acid
  5. 9,181,331 Pharmaceutical compositions for binding sphingosine-1-phosphate
  6. 9,163,091 Compositions and methods for binding lysophosphatidic acid
  7. 9,017,986 Minicell based delivery of biologically active compounds
  8. 8,871,202 Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
  9. 8,796,429 Bioactive lipid derivatives, and methods of making and using same
  10. 8,614,103 Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
  11. 8,604,172 Humanized antibody compositions and methods for binding lysophosphatidic acid
  12. 8,524,484 Immunogenic minicells and methods of use
  13. 8,444,970 Compositions and methods for treating ocular diseases and conditions
  14. 8,401,799 Antibody design using anti-lipid antibody crystal structures
  15. 8,361,465 Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
  16. 8,222,373 Humanized antibodies and compositions for binding sphingosine-1-phosphate
  17. 8,158,124 Compositions and methods for binding lysophosphatidic acid
  18. 8,129,166 Immunogenic minicells and methods of use
  19. 8,101,396 Minicells displaying antibodies or derivatives thereof and comprising biologically active compounds
  20. 8,067,549 Humanized antibodies and compositions for binding sphingosine-1-phosphate
  21. 8,026,342 Compositions and methods for binding sphingosine-1-phosphate
  22. 8,025,877 Methods of using humanized antibodies and compositions for binding sphingosine-1-phosphate
  23. 7,956,173 Nucleic acids coding for humanized antibodies for binding sphingosine-1-phosphate
  24. 7,901,682 Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation
  25. 7,871,815 Rhamnose-inducible expression constructs and methods
  26. 7,862,812 Methods for decreasing immune response and treating immune conditions
  27. 7,829,674 Compositions and methods for binding sphingosine-1-phosphate
  28. 7,794,713 Compositions and methods for the treatment and prevention of hyperproliferative diseases
  29. 7,396,822 Immunogenic minicells and methods of use
  30. 7,183,105 Eubacterial minicells and their use as vectors for nucleic acid delivery and expression
  31. 7,169,390 Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation
  32. 6,881,546 Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
  33. 6,858,383 Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
  34. 6,534,323 Compositions and methods for early detection of heart disease
  35. 6,534,322 Kits for early detection of heart disease
  36. 6,210,976 Methods for early detection of heart disease
Media

  1. Sabbadini has 36 issued US patents. Sabbadini was interviewed at an 2018 international scientific conference in Padova, Italy

Fun Facts
  1. [A]
  2. [B]
  3. [C]